An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus

Amit Thakral; Marisa S. Klein-Gitelman

doi:10.1007/s40744-016-0044-0

An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus

Amit Thakral^*, Marisa S. Klein-Gitelman

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which 20 % of patients are diagnosed in childhood. Childhood-onset SLE is associated with higher morbidity and mortality than adult-onset SLE. The aims of disease management with early immunosuppression are to decrease disease activity and improve quality of life. A multidisciplinary approach is necessary due to the complexity of lupus in pediatric patients. It is important to provide patients with high quality of care and to instill ownership of their disease process from a young age to prepare them to manage this life-long illness. This article reviews current management of SLE in children.

Original language	English (US)
Pages (from-to)	209-219
Number of pages	11
Journal	Rheumatology and Therapy
Volume	3
Issue number	2
DOIs	https://doi.org/10.1007/s40744-016-0044-0
State	Published - Dec 2016

Funding

No funding or sponsorship was received for the publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. A. Thakral and M. S. Klein-Gitelman have nothing to disclose. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Keywords

Autoimmune
Management
Medication
Pediatric
Rheumatology
Systemic lupus erythematosus
Treatment

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy

Access to Document

10.1007/s40744-016-0044-0

Cite this

@article{820f6f5e55884bbaa173e725342604e0,

title = "An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus",

abstract = "Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which 20 % of patients are diagnosed in childhood. Childhood-onset SLE is associated with higher morbidity and mortality than adult-onset SLE. The aims of disease management with early immunosuppression are to decrease disease activity and improve quality of life. A multidisciplinary approach is necessary due to the complexity of lupus in pediatric patients. It is important to provide patients with high quality of care and to instill ownership of their disease process from a young age to prepare them to manage this life-long illness. This article reviews current management of SLE in children.",

keywords = "Autoimmune, Management, Medication, Pediatric, Rheumatology, Systemic lupus erythematosus, Treatment",

author = "Amit Thakral and Klein-Gitelman, {Marisa S.}",

note = "Funding Information: No funding or sponsorship was received for the publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. A. Thakral and M. S. Klein-Gitelman have nothing to disclose. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Publisher Copyright: {\textcopyright} 2016, The Author(s).",

year = "2016",

month = dec,

doi = "10.1007/s40744-016-0044-0",

language = "English (US)",

volume = "3",

pages = "209--219",

journal = "Rheumatology and Therapy",

issn = "2198-6576",

publisher = "Adis International Ltd",

number = "2",

}

TY - JOUR

T1 - An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus

AU - Thakral, Amit

AU - Klein-Gitelman, Marisa S.

N1 - Funding Information: No funding or sponsorship was received for the publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. A. Thakral and M. S. Klein-Gitelman have nothing to disclose. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Publisher Copyright: © 2016, The Author(s).

PY - 2016/12

Y1 - 2016/12

N2 - Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which 20 % of patients are diagnosed in childhood. Childhood-onset SLE is associated with higher morbidity and mortality than adult-onset SLE. The aims of disease management with early immunosuppression are to decrease disease activity and improve quality of life. A multidisciplinary approach is necessary due to the complexity of lupus in pediatric patients. It is important to provide patients with high quality of care and to instill ownership of their disease process from a young age to prepare them to manage this life-long illness. This article reviews current management of SLE in children.

AB - Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which 20 % of patients are diagnosed in childhood. Childhood-onset SLE is associated with higher morbidity and mortality than adult-onset SLE. The aims of disease management with early immunosuppression are to decrease disease activity and improve quality of life. A multidisciplinary approach is necessary due to the complexity of lupus in pediatric patients. It is important to provide patients with high quality of care and to instill ownership of their disease process from a young age to prepare them to manage this life-long illness. This article reviews current management of SLE in children.

KW - Autoimmune

KW - Management

KW - Medication

KW - Pediatric

KW - Rheumatology

KW - Systemic lupus erythematosus

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85037630909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037630909&partnerID=8YFLogxK

U2 - 10.1007/s40744-016-0044-0

DO - 10.1007/s40744-016-0044-0

M3 - Review article

C2 - 27747587

AN - SCOPUS:85037630909

SN - 2198-6576

VL - 3

SP - 209

EP - 219

JO - Rheumatology and Therapy

JF - Rheumatology and Therapy

IS - 2

ER -

An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this